<DOC>
	<DOC>NCT00767585</DOC>
	<brief_summary>The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.</brief_summary>
	<brief_title>An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women aged 5565 years, diagnosed with invasive early breast cancer: Surgery, chemo and/or radiotherapy concluded less than 6 months ago Women with hormoneindependent breast cancer: Surgery, chemo and/or radiotherapy concluded before 2436 months or 5466 months Women with hormonedependent breast cancer: Adjuvant therapy with tamoxifen initiated before 2436 and 5466 months or Adjuvant therapy with aromatase inhibitor initiated before 2436 and 5466 months or Switch from tamoxifen to aromatase inhibitor initiated before 2436 months Women receiving active treatment for osteoporosis Women with any evidence of breast cancer recurrence</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitors</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>osteoporosis</keyword>
</DOC>